RET and lung carcinoma: Several multiple kinase inhibitors (vandetanib, cabozantinib, RXDX-105, and levantinib) and RET-specific inhibitors (pralsetinib and selpercatinib) with modest inhibitory activity have been developed for the treatment of RET-positive lung cancer patients.